Santarus (SNTS) Stock Price, News & Analysis

Company Overview

Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company's marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company's investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Key Stats

• Today's Range: N/A
• 50-Day Range: $16,995.00 to $16,995.00
• 52-Week Range: N/A
• Volume: 54,432 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNTS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Santarus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Santarus investors own include Bristol Myers Squibb (BMY), Meta Platforms (META), Yelp (YELP), Altaba (AABA), Allergan (AGN), Baidu (BIDU) and Ford Motor (F).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SNTS
• CIK: 1172480
• Web: www.santarus.com
• Phone: +1-858-3145700
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A